{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Genmab Portfolio Prioritization Update - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"1NXGiJnvD8\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/\">Genmab Portfolio Prioritization Update<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/embed\/#?secret=1NXGiJnvD8\" width=\"600\" height=\"338\" title=\"&#8220;Genmab Portfolio Prioritization Update&#8221; &#8212; Market Newsdesk\" data-secret=\"1NXGiJnvD8\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Genmab Portfolio Prioritization Update Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher\u2011impact opportunities across Genmab\u2019s late\u2011stage pipeline and increasingly competitive landscape This decision does not impact Genmab\u2019s full\u2011year 2025 financial guidance COPENHAGEN, Denmark&#8211;(BUSINESS WIRE)&#8211;Genmab A\/S (Nasdaq: GMAB) announced today thatit will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab\u2019s strategic focus on the most value\u2011creating opportunities in its late\u2011stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including EPKINLY\u00ae (epcoritamab), petosemtamab and rinatabart sesutecan (Rina\u2011S\u00ae), which are advancing in late\u2011stage &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"}